8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 10, 2026·SEC
Exagen Inc.(XGN)Earnings, Financials & Key Ratios
XGN•NASDAQ
Price updated Jun 23, 2026
AboutExagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Show more
- Revenue$67M+19.7%
- EBITDA-$12M-0.3%
- Net Income-$20M-32.0%
- EPS (Diluted)-0.93-12.0%
- Gross Margin58.28%-2.1%
- EBITDA Margin-17.95%+16.1%
- Operating Margin-21.13%+13.8%
- Net Margin-29.97%-10.3%
- ROE-147.85%-57.6%
XGN Key Insights
Exagen Inc. (XGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 18.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XGN Price & Volume
Exagen Inc. (XGN) stock price & volume — 10-year historical chart
Loading chart...
XGN Growth Metrics
Exagen Inc. (XGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.03%
5 Years9.66%
3 Years13.47%
TTM20.55%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.14%
Return on Capital
10 Years-176.37%
5 Years-37.06%
3 Years-36.94%
Last Year-37.5%
XGN Recent Earnings
Exagen Inc. (XGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.17+29.2%
$0.24
Rev
$17M+5.5%
$16M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.20+0.0%
$0.20
Rev
$17M+0.4%
$17M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.19-46.2%
$0.13
Rev
$17M+4.3%
$17M
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.18+0.0%
$0.18
Rev
$17M+1.8%
$17M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.17vs $0.24+29.2% | $17Mvs $16M+5.5% |
| Q2 2026 | Mar 10, 2026 | $0.20vs $0.20+0.0% | $17Mvs $17M+0.4% |
| Q4 2025 | Nov 4, 2025 | $0.19vs $0.13-46.2% | $17Mvs $17M+4.3% |
| Q3 2025 | Jul 29, 2025 | $0.18vs $0.18+0.0% | $17Mvs $17M+1.8% |
Based on last 12 quarters of dataView full earnings history →
XGN Peer Comparison
Exagen Inc. (XGN) competitors in Clinical and Specialty Lab Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CDNA | 1.3B | 25.12 | -62.80 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 33.62B | 234.76 | -154.45 | 35.9% | -9.05% | -15.13% | 0.13 | |
 VCYT | 4.29B | 53.79 | 65.60 | 16.01% | 16.25% | 6.86% | 0.03 | |
 CSTL | 648.45M | 21.38 | -25.76 | 3.66% | -3.77% | -2.77% | 0.08 | |
 MYGN | 432.94M | 4.63 | -1.17 | -1.56% | -48.24% | -109.09% | 0.57 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 GH | 17.35B | 130.83 | -39.41 | 32.88% | -40.1% | |||
 FLGT | 516.32M | 18.18 | -9.23 | 13.83% | -23.04% | -6.74% | 0.01 |
Compare XGN vs Peers
Exagen Inc. (XGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XGN Income Statement
Exagen Inc. (XGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 26.81M | 32.44M | 40.39M | 41.98M | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M | 68.38M |
Revenue Growth % | 49.38% | 21.01% | 24.5% | 3.93% | 15.07% | -5.66% | 15.33% | 5.89% | 19.65% | 20.55% |
Cost of Goods Sold | 14.14M | 15.38M | 18.81M | 16.56M | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M | 28.5M |
COGS % of Revenue | 52.74% | 47.41% | 46.57% | 39.45% | 42.63% | 53.14% | 43.94% | 40.49% | 41.72% | - |
Gross Profit | 12.67M▲ 0% | 17.06M▲ 34.7% | 21.58M▲ 26.5% | 25.42M▲ 17.8% | 27.71M▲ 9.0% | 21.35M▼ 23.0% | 29.46M▲ 38.0% | 33.11M▲ 12.4% | 38.8M▲ 17.2% | 39.88M▲ 0% |
Gross Margin % | 47.26% | 52.59% | 53.43% | 60.55% | 57.37% | 46.86% | 56.06% | 59.51% | 58.28% | 58.32% |
Gross Profit Growth % | 50.6% | 34.66% | 26.48% | 17.78% | 9.03% | -22.96% | 37.97% | 12.41% | 17.18% | - |
Operating Expenses | 20.56M | 21.94M | 30.88M | 40.6M | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M | 54M |
OpEx % of Revenue | 76.69% | 67.64% | 76.46% | 96.73% | 107.2% | 147.93% | 99.51% | 84.02% | 79.41% | - |
Selling, General & Admin | 18.82M | 19.68M | 28.7M | 37.03M | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M | 47.48M |
SG&A % of Revenue | 70.21% | 60.65% | 71.07% | 88.23% | 92.22% | 114.17% | 90.26% | 74.36% | 70.02% | - |
Research & Development | 1.55M | 2.13M | 2.18M | 3.57M | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M | 6.52M |
R&D % of Revenue | 5.79% | 6.55% | 5.39% | 8.5% | 14.98% | 21.68% | 9.26% | 9.66% | 9.39% | - |
Other Operating Expenses | 186K | 141K | 0 | 0 | 0 | 5.51M | 0 | 0 | 0 | 0 |
Operating Income | -7.84M▲ 0% | -4.88M▲ 37.7% | -9.3M▼ 90.6% | -15.19M▼ 63.3% | -24.07M▼ 58.5% | -46.05M▼ 91.3% | -22.84M▲ 50.4% | -13.64M▲ 40.3% | -14.07M▼ 3.2% | -14.12M▲ 0% |
Operating Margin % | -29.23% | -15.04% | -23.02% | -36.18% | -49.83% | -101.07% | -43.46% | -24.51% | -21.13% | -20.65% |
Operating Income Growth % | 24.57% | 37.72% | -90.55% | -63.3% | -58.49% | -91.34% | 50.41% | 40.29% | -3.18% | - |
EBITDA | -7.17M | -4.15M | -8.71M | -14.64M | -23.12M | -44.49M | -20.67M | -11.91M | -11.95M | -12.59M |
EBITDA Margin % | -26.73% | -12.79% | -21.56% | -34.88% | -47.87% | -97.65% | -39.33% | -21.41% | -17.95% | -18.41% |
EBITDA Growth % | 24.64% | 42.1% | -109.88% | -68.11% | -57.93% | -92.46% | 53.55% | 42.37% | -0.34% | -2.4% |
D&A (Non-Cash Add-back) | 670K | 731K | 591K | 546K | 948K | 1.56M | 2.17M | 1.72M | 2.12M | 1.53M |
EBIT | -23.23M | -5.09M | -8.52M | -14.2M | -24.05M | -45.22M | -21.32M | -12.87M | -14.07M | -17.44M |
Net Interest Income | -2.9M | -2.87M | -3.49M | -2.56M | -2.61M | -1.62M | -819K | -1.47M | -4.03M | -2.38M |
Interest Income | 45K | 0 | 0 | 0 | 16K | 830K | 1.52M | 767K | 289K | 128K |
Interest Expense | 2.95M | 2.87M | 3.49M | 2.56M | 2.63M | 2.45M | 2.33M | 2.23M | 4.32M | 2.5M |
Other Income/Expense | -18.34M | -3.07M | -2.71M | -1.58M | -2.61M | -1.62M | -819K | -1.47M | -5.83M | -5.96M |
Pretax Income | -26.18M▲ 0% | -7.95M▲ 69.6% | -12.01M▼ 51.0% | -16.77M▼ 39.6% | -26.68M▼ 59.1% | -47.67M▼ 78.7% | -23.66M▲ 50.4% | -15.1M▲ 36.2% | -19.9M▼ 31.8% | -20.08M▲ 0% |
Pretax Margin % | -97.66% | -24.52% | -29.74% | -39.94% | -55.23% | -104.62% | -45.02% | -27.14% | -29.89% | -29.36% |
Income Tax | -549K | 58K | 25K | -79K | 175K | -282K | 33K | 12K | 51K | 87K |
Effective Tax Rate % | 2.1% | -0.73% | -0.21% | 0.47% | -0.66% | 0.59% | -0.14% | -0.08% | -0.26% | -0.43% |
Net Income | -25.63M▲ 0% | -8.01M▲ 68.7% | -12.04M▼ 50.2% | -16.69M▼ 38.6% | -26.85M▼ 60.9% | -47.39M▼ 76.5% | -23.69M▲ 50.0% | -15.12M▲ 36.2% | -19.95M▼ 32.0% | -20.17M▲ 0% |
Net Margin % | -95.61% | -24.7% | -29.81% | -39.75% | -55.59% | -104% | -45.08% | -27.17% | -29.97% | -29.49% |
Net Income Growth % | -33.61% | 68.74% | -50.25% | -38.62% | -60.91% | -76.48% | 50.01% | 36.19% | -31.99% | -30.04% |
Net Income (Continuing) | -25.63M | -8.01M | -12.04M | -16.69M | -26.85M | -47.39M | -23.69M | -15.12M | -19.95M | -20.17M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -406.81▲ 0% | -127.16▲ 68.7% | -0.96▲ 99.2% | -1.32▼ 37.5% | -1.68▼ 27.3% | -2.77▼ 64.9% | -1.34▲ 51.6% | -0.83▲ 38.1% | -0.93▼ 12.0% | -0.85▲ 0% |
EPS Growth % | -33.17% | 68.74% | 99.25% | -37.5% | -27.27% | -64.88% | 51.62% | 38.06% | -12.05% | -7.14% |
EPS (Basic) | -406.81 | -127.16 | -0.96 | -1.32 | -1.68 | -2.77 | -1.34 | -0.83 | -0.93 | - |
Diluted Shares Outstanding | 63.01K | 63.01K | 12.56M | 12.65M | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M | 23.85M |
Basic Shares Outstanding | 63.01K | 63.01K | 12.56M | 12.65M | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M | 23.85M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XGN Balance Sheet
Exagen Inc. (XGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 13.26M | 21.31M | 81.25M | 70.52M | 112.73M | 72.61M | 47.84M | 36.45M | 48.89M | 43.58M |
Cash & Short-Term Investments | 11.24M | 13.16M | 72.08M | 57.45M | 99.44M | 62.39M | 36.49M | 22.04M | 32.22M | 21.51M |
Cash Only | 11.24M | 13.16M | 72.08M | 57.45M | 99.44M | 62.39M | 36.49M | 22.04M | 32.22M | 21.51M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 604K | 5.95M | 5.71M | 8.91M | 9.65M | 6.08M | 6.55M | 7.83M | 10.86M | 15.77M |
Days Sales Outstanding | 8.22 | 66.97 | 51.65 | 77.48 | 72.96 | 48.68 | 45.5 | 51.4 | 59.51 | 70.89 |
Inventory | 544K | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 14.05 | 24.26 | - | - | - | - | - | - | - | 11.29 |
Other Current Assets | 871K | 1.17M | 0 | 0 | 490K | 236K | 1.93M | 859K | 5.82M | 6.3M |
Total Non-Current Assets | 7.13M | 7.58M | 7.06M | 7.86M | 10.71M | 13.61M | 9.1M | 8.23M | 9.13M | 8.37M |
Property, Plant & Equipment | 1.34M | 1.57M | 1.38M | 2.1M | 4.77M | 13.08M | 8.49M | 7.68M | 8.37M | 7.79M |
Fixed Asset Turnover | 19.96x | 20.72x | 29.27x | 19.97x | 10.12x | 3.48x | 6.19x | 7.24x | 7.95x | 8.59x |
Goodwill | 5.51M | 5.51M | 5.51M | 5.51M | 5.51M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 141K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 100K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 400K |
Other Non-Current Assets | -348K | -24K | 174K | 250K | 433K | 528K | 616K | 550K | 556K | 584K |
Total Assets | 20.39M▲ 0% | 28.89M▲ 41.7% | 88.31M▲ 205.7% | 78.38M▼ 11.3% | 123.44M▲ 57.5% | 86.22M▼ 30.2% | 56.94M▼ 34.0% | 44.69M▼ 21.5% | 58.02M▲ 29.8% | 51.96M▲ 0% |
Asset Turnover | 1.31x | 1.12x | 0.46x | 0.54x | 0.39x | 0.53x | 0.92x | 1.25x | 1.15x | 1.18x |
Asset Growth % | 39.4% | 41.67% | 205.71% | -11.25% | 57.51% | -30.15% | -33.96% | -21.52% | 29.84% | 122.02% |
Total Current Liabilities | 4.99M | 8.95M | 5.89M | 8.77M | 9.32M | 9.62M | 11.9M | 13.51M | 14.16M | 12.56M |
Accounts Payable | 1.77M | 1.28M | 1.48M | 3.01M | 2.49M | 3.05M | 3.13M | 4.14M | 4.15M | 4.16M |
Days Payables Outstanding | 45.75 | 30.36 | 28.64 | 66.44 | 44.18 | 45.92 | 49.49 | 67.02 | 54.57 | 46.04 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 190K | 264K | 423K | 3M | 2.95M |
Deferred Revenue (Current) | 0 | 3.84M | 0 | 0 | 0 | 0 | 0 | 0 | 675K | 3.01M |
Other Current Liabilities | 1.22M | 4.11M | 0 | 0 | 0 | 445K | 0 | 0 | 6.33M | 4.77M |
Current Ratio | 2.66x | 2.38x | 13.78x | 8.04x | 12.10x | 7.55x | 4.02x | 2.70x | 3.45x | 3.47x |
Quick Ratio | 2.55x | 2.27x | 13.78x | 8.04x | 12.10x | 7.55x | 4.02x | 2.70x | 3.45x | 3.47x |
Cash Conversion Cycle | -23.48 | 60.87 | - | - | - | - | - | - | - | 36.13 |
Total Non-Current Liabilities | 20.04M | 26.67M | 26.76M | 27.77M | 29.19M | 34.14M | 22.35M | 21.64M | 26.41M | 24.96M |
Long-Term Debt | 18.81M | 24.62M | 25.85M | 26.66M | 27.48M | 28.78M | 19.23M | 19.82M | 2.4M | 1.9M |
Capital Lease Obligations | 81K | 279K | 0 | 0 | 0 | 4.49M | 2.76M | 1.66M | 0 | 6.37M |
Deferred Tax Liabilities | 214K | 245K | 264K | 158K | 306K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -644K | -1.23M | 638K | 948K | 1.41M | 867K | 357K | 157K | 24.02M | 23.06M |
Total Liabilities | 25.03M | 35.62M | 32.65M | 36.54M | 38.51M | 43.76M | 34.25M | 35.15M | 40.57M | 37.52M |
Total Debt | 18.84M | 24.7M | 26.09M | 26.97M | 28.07M | 35.2M | 23.23M | 23M | 5.4M | 4.86M |
Net Debt | 7.59M | 11.53M | -45.99M | -30.48M | -71.38M | -27.19M | -13.26M | 969K | -26.82M | -16.66M |
Debt / Equity | - | - | 0.47x | 0.64x | 0.33x | 0.83x | 1.02x | 2.41x | 0.31x | 0.34x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.39x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.32x |
Interest Coverage | -7.88x | -1.77x | -2.44x | -5.54x | -9.16x | -18.47x | -9.13x | -5.76x | -3.26x | -6.97x |
Total Equity | -4.64M▲ 0% | -6.73M▼ 45.2% | 55.66M▲ 926.5% | 41.84M▼ 24.8% | 84.94M▲ 103.0% | 42.46M▼ 50.0% | 22.69M▼ 46.6% | 9.54M▼ 58.0% | 17.45M▲ 82.9% | 14.43M▲ 0% |
Equity Growth % | 79.09% | -45.19% | 926.54% | -24.83% | 103.01% | -50.01% | -46.55% | -57.96% | 82.9% | 268.87% |
Book Value per Share | -73.61 | -106.88 | 4.43 | 3.31 | 5.32 | 2.49 | 1.28 | 0.52 | 0.81 | 0.60 |
Total Shareholders' Equity | -4.64M | -6.73M | 55.66M | 41.84M | 84.94M | 42.46M | 22.69M | 9.54M | 17.45M | 14.43M |
Common Stock | 12K | 12K | 13K | 13K | 16K | 17K | 17K | 18K | 23K | 24K |
Retained Earnings | -147.64M | -152.56M | -164.6M | -181.29M | -208.14M | -255.53M | -279.22M | -294.33M | -314.28M | -318.25M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.18M | -1.82M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XGN Cash Flow Statement
Exagen Inc. (XGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.97M | -9.3M | -9.71M | -14.08M | -20.27M | -32.14M | -14.46M | -13.28M | -13.63M | -13.37M |
Operating CF Margin % | -40.91% | -28.67% | -24.04% | -33.55% | -41.97% | -70.55% | -27.52% | -23.87% | -20.47% | - |
Operating CF Growth % | 7.85% | 15.2% | -4.41% | -45.03% | -43.92% | -58.59% | 55.01% | 8.18% | -2.61% | -711.27% |
Net Income | -25.63M | -8.01M | -12.04M | -16.69M | -26.85M | -47.39M | -23.69M | -15.12M | -19.95M | -20.17M |
Depreciation & Amortization | 670K | 731K | 591K | 546K | 948K | 1.56M | 2.17M | 1.72M | 2.12M | 2.28M |
Stock-Based Compensation | 187K | 114K | 572K | 2.69M | 4.73M | 4.7M | 3.62M | 1.76M | 2.16M | 1.69M |
Deferred Taxes | -554K | 31K | -247K | -106K | 148K | -306K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 16.38M | 1.43M | 1.24M | 805K | 819K | 7.62M | 3.12M | 1.43M | 4.03M | 4.46M |
Working Capital Changes | -2.02M | -3.59M | 174K | -1.34M | -61K | 1.67M | 325K | -3.08M | -1.98M | -1.63M |
Change in Receivables | -198K | -2.26M | 237K | -3.19M | -744K | 3.58M | -474K | -1.28M | -3.02M | -1.04M |
Change in Inventory | 436K | -497K | -567K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 44K | -824K | 528K | 986K | -655K | 901K | 67K | 308K | 42K | -230K |
Cash from Investing | -510K | -199K | -103K | -455K | -2.42M | -4.32M | -804K | -515K | -626K | -747K |
Capital Expenditures | -567K | -199K | -403K | -455K | -2.37M | -4.32M | -828K | -515K | -641K | -756K |
CapEx % of Revenue | 2.12% | 0.61% | 1% | 1.08% | 4.91% | 9.48% | 1.58% | 0.93% | 0.96% | 1.11% |
Acquisitions | 57K | 0 | 300K | 0 | 0 | 0 | 0 | 0 | 15K | 9K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 57K | 0 | 0 | 0 | -50K | 0 | 24K | 0 | 0 | 0 |
Cash from Financing | 19.16M | 11.42M | 68.73M | -97K | 64.68M | -489K | -10.63M | -663K | 24.43M | 24.44M |
Debt Issued (Net) | 4.51M | 4.96M | -138K | -249K | -525K | -696K | -10.94M | -861K | 2.01M | 1.92M |
Equity Issued (Net) | 0 | 0 | 68.87M | 173K | 69.14M | 446K | 306K | 198K | 22.42M | 22.52M |
Dividends Paid | 0 | 0 | -6.74M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K |
Other Financing | 14.64M | 6.47M | 6.74M | -21K | -3.94M | -239K | 0 | 0 | 0 | 0 |
Net Change in Cash | 7.68M▲ 0% | 1.92M▼ 75.0% | 58.92M▲ 2964.0% | -14.64M▼ 124.8% | 41.99M▲ 386.9% | -36.95M▼ 188.0% | -25.9M▲ 29.9% | -14.46M▲ 44.2% | 10.18M▲ 170.4% | 10.32M▲ 0% |
Free Cash Flow | -11.54M▲ 0% | -9.5M▲ 17.6% | -10.11M▼ 6.5% | -14.54M▼ 43.8% | -22.64M▼ 55.7% | -36.46M▼ 61.1% | -15.29M▲ 58.1% | -13.79M▲ 9.8% | -14.27M▼ 3.4% | -14.13M▲ 0% |
FCF Margin % | -43.03% | -29.28% | -25.04% | -34.64% | -46.87% | -80.03% | -29.1% | -24.79% | -21.43% | -20.66% |
FCF Growth % | 9.22% | 17.64% | -6.46% | -43.75% | -55.71% | -61.06% | 58.07% | 9.78% | -3.42% | 8.57% |
FCF per Share | -183.08 | -150.78 | -0.81 | -1.15 | -1.42 | -2.13 | -0.86 | -0.76 | -0.66 | -0.59 |
FCF Conversion (FCF/Net Income) | 0.43x | 1.16x | 0.81x | 0.84x | 0.75x | 0.68x | 0.61x | 0.88x | 0.68x | 0.70x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XGN Key Ratios
Exagen Inc. (XGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -49.21% | -34.23% | -42.36% | -74.39% | -72.72% | -93.78% | -147.85% | -113.53% |
Return on Invested Capital (ROIC) | -282.07% | -94.37% | -96.42% | -108.34% | -144.88% | -239.61% | -138.67% | -102.57% | -1851.32% | -112.87% |
Gross Margin | 47.26% | 52.59% | 53.43% | 60.55% | 57.37% | 46.86% | 56.06% | 59.51% | 58.28% | 58.32% |
Net Margin | -95.61% | -24.7% | -29.81% | -39.75% | -55.59% | -104% | -45.08% | -27.17% | -29.97% | -29.49% |
Debt / Equity | - | - | 0.47x | 0.64x | 0.33x | 0.83x | 1.02x | 2.41x | 0.31x | 0.34x |
Interest Coverage | -7.88x | -1.77x | -2.44x | -5.54x | -9.16x | -18.47x | -9.13x | -5.76x | -3.26x | -6.97x |
FCF Conversion | 0.43x | 1.16x | 0.81x | 0.84x | 0.75x | 0.68x | 0.61x | 0.88x | 0.68x | 0.70x |
Revenue Growth | 49.38% | 21.01% | 24.5% | 3.93% | 15.07% | -5.66% | 15.33% | 5.89% | 19.65% | 20.55% |
Related:XGN Dividend History·XGN Revenue History·XGN Price History·XGN P/E History·XGN Financial Ratios·XGN Institutional Holders
XGN SEC Filings & Documents
Exagen Inc. (XGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
XGN Frequently Asked Questions
Exagen Inc. (XGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Exagen Inc. (XGN) reported $68.4M in revenue for fiscal year 2025. This represents a 7285% increase from $0.9M in 2012.
Exagen Inc. (XGN) grew revenue by 19.7% over the past year. This is strong growth.
Exagen Inc. (XGN) reported a net loss of $20.2M for fiscal year 2025.
Dividend & Returns
Exagen Inc. (XGN) has a return on equity (ROE) of -147.8%. Negative ROE indicates the company is unprofitable.
Exagen Inc. (XGN) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.